$150M Equity Offering Launched Days After REGAL Trial Win
SLS has more than doubled off its 52-week low of $1.39 on elevated volume (13× avg).
Summary
SELLAS launched a $150.0 million underwritten public offering of common stock, with a 30-day option for up to $22.5 million more. J.P. Morgan and TD Cowen are joint book-running managers. The raise is large relative to the company and comes just hours after the stock jumped on positive Phase 3 REGAL overall survival data, so expect dilution pressure and a likely discount to the $18.03 last price once terms are set. The company already had $134.7 million in cash as of Q3, enough for at least twelve months, so this is opportunistic capital ahead of BLA preparation rather than a liquidity scramble. Pricing terms and the final size are the next hard data points.
At the time of this announcement, SLS was trading at $18.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.39 to $24.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.